
DALLAS, Nov. 2022 — In a news release, the American Heart Association® announced the extension of its Target: Aortic Stenosis™ initiative, which seeks to improve the identification and quality of care of patients with aortic stenosis—starting at symptom onset and continuing through diagnosis, treatment, and management.
Aortic stenosis is a progressive heart disease involving a narrowed opening of a heart valve and, according to the American Heart Association, up to 1.6 million American over the age of 65 live with severe symptomatic aortic stenosis. Without a valve replacement procedure, as few as half of those patients survive more than two years.
The program initially launched in 2020 with support from Edwards Lifesciences at 15 sites across the United States in order to develop guidelines for optimal measurement to improve identification of patient with aortic stenosis, as well as provide multi-media educational and self-management resources for patients with structural heart disease.